Bacopa Monnieri (Brahmi)
Bacopa monnieri (also called Brahmi or water hyssop) is a creeping perennial herb native to wetlands across India, Australia, and southern Africa. It has a long history of use in traditional Ayurvedic medicine for cognitive and nervous-system support and is sold in the UK as a food supplement, typically as a standardised extract of the aerial parts. There are no authorised UK food-supplement health claims for Bacopa. Trial evidence for cognitive function in healthy adults exists but is small-scale and is concentrated on specific standardised extracts at specific durations (8–12 weeks).
Camden Medicals editorial · Last reviewed 1 May 2026 · Next review November 2026
- Cross-checked against
- NHS
- NICE
- BNF
- EFSA
- FSA
Camden's editorial team independently graded each health claim below on the strength of the published evidence — see the grade beside every condition.
- Class
- Botanical
- Typical daily dose
- Trials of standardised Bacopa extract have most commonly used 300–450 mg/day of extract standardised to ≥20% bacosides (e.g. Bacopa CDRI 08 300 mg/day; BacoMind® 320 mg/day). Whole-herb powder at the same milligram delivers a lower bacoside dose and is not directly comparable.
- Top use evidence
- Limited
On this page
What it is
Bacopa monnieri is a small succulent creeping herb in the Plantaginaceae family, native to wetland and marshy habitats across the Indian subcontinent, Australia, and parts of southern Africa. It has been used in Ayurvedic medicine for at least two thousand years for memory, cognitive, and nervous-system applications, and is one of the most-studied "nootropic" botanicals in modern trial literature.
The bioactive compounds most discussed are the bacosides — a family of saponin glycosides including bacosides A1, A2, A3, and bacoside B. Most modern clinical trials have used standardised extracts declaring bacoside A content (typically 20–55%). Bacopa CDRI 08 (a research-grade preparation developed at India''s Central Drug Research Institute) and BacoMind® (a multi-bacoside standardised extract) are the two preparations with the most trial use.
The mushroom-supplement-style quality framework also applies here: standardisation by the relevant bioactive (bacoside A%) matters more than the milligram of dried herb on the label. A 500 mg capsule of dried Bacopa powder and a 500 mg capsule of Bacopa extract standardised to 50% bacosides are not comparable.
At a glance
- A traditional Ayurvedic herb (Bacopa monnieri / Brahmi) sold in the UK as a food supplement.
- No UK-authorised health claims; EFSA evaluation on hold for botanicals.
- Trials are concentrated on specific standardised extracts (notably Bacopa CDRI 08 and BacoMind®) standardised to bacoside A content. Generic "Bacopa powder" at the same milligram tells you nothing comparable.
- Effect sizes are modest and emerge over 8–12 weeks of daily use, not acutely. There is no reliable single-dose effect.
- GI complaints (nausea, cramping, soft stools) are the most common side effect. Take with food.
What people use it for
Adults exploring chronic-use cognitive supplementation in healthy ageing
A small literature reports modest improvements in delayed verbal recall and information processing after 8–12 weeks of standardised Bacopa extract. Effect sizes are modest. UK NHS pathways for cognitive concerns do not list Bacopa. [2]
Some evidenceLimitedAdults considering supplements for diagnosed cognitive impairment, dementia, or mental-health conditions
Bacopa is not a treatment for these conditions. UK NHS pathways apply. Talk to your GP. [1,2]
Popular, not provenInsufficientStudents or working adults wanting an acute focus boost
Bacopa is a chronic-use supplement in trial protocols. There is no reliable single-dose acute focus effect. If acute focus is the goal, this is not the right ingredient.
Popular, not provenInsufficientAdults exploring traditional Ayurvedic botanicals
Long history of traditional use in Ayurvedic medicine. Traditional-use framing is permissible; specific health claims are not authorised.
Some evidenceLimited
How it works
Multiple mechanisms have been proposed for bacosides: modulation of cholinergic neurotransmission (acetylcholine signalling), antioxidant effects on neural tissue, dendritic-arborisation effects in animal models, and neurotrophic signalling. Trials in healthy adults have reported modest improvements in tests of delayed verbal recall and information processing speed after 8–12 weeks of daily supplementation. The acute / single-dose cognitive effect is small and inconsistent — Bacopa is positioned as a chronic-use cognitive supplement in trial protocols, not as an acute nootropic.
Common myths
Myth"Bacopa is a "natural Adderall""
RealityIt is not. Adderall (mixed amphetamine salts) is a Prescription-Only Medicine — a controlled stimulant with well-defined dose-response, dependence liability, and prescribing rules. Bacopa is a chronic-use food supplement with modest cognitive effect sizes after 8–12 weeks of daily use. The "natural Adderall" framing is marketing language, not clinical equivalence.
Myth"Bacopa works the first day you take it"
RealityTrials have reported cognitive effects emerging at 8–12 weeks, not acutely. The acute / single-dose effect is small and inconsistent. Marketing implying same-day cognitive boost is not supported by trial protocols.
Myth"A "10:1 Bacopa extract" is ten times stronger than the powder"
RealityExtract ratios describe how many kilograms of starting raw Bacopa were processed to yield one kilogram of extract. They do not describe the bacoside content. The relevant marker is bacoside A standardisation percentage. A "10:1 extract" with no bacoside standardisation tells you nothing comparable to the trial materials.
Myth"Bacopa cures dementia"
RealityIt does not. UK NICE pathways for dementia (NG97) do not list Bacopa. Marketing implying treatment of dementia operates outside both the evidence base and UK supplement-marketing rules. [2]
Common online questions
Synthesised from the questions UK shoppers most often ask online about Bacopa Monnieri (Brahmi). Each answer is editorial and links to its evidence in the Sources list below.
How long does Bacopa take to work?
The published trials report effects emerging at 8–12 weeks of daily use. There is no reliable single-dose acute cognitive effect — Bacopa is a chronic-use supplement in the trial literature, not an acute nootropic. If you don''t notice anything in the first weeks, that is consistent with the trial evidence.
Standardised extract vs whole-herb powder — which?
For trial-comparable supplementation, standardised extract is what the literature has used. Look for bacoside A standardisation declared on the label (typically 20–55%) and ideally a research-grade preparation name (Bacopa CDRI 08 or BacoMind®). Whole-herb powder at the same milligram delivers a lower and unstandardised bacoside dose.
Can children take Bacopa?
Some trials have explored Bacopa in children with ADHD. UK NHS / NICE pathways for ADHD (NG87) apply for diagnosis and management. Self-supplementing a child with Bacopa for attention concerns is not the appropriate pathway. Talk to your child''s GP and if a trial is a discussion you want, have it with the clinician managing them. [3]
Can I take Bacopa with my antidepressant or anti-anxiety medication?
Talk to your prescribing pharmacist or GP first. Bacopa''s proposed mechanisms (cholinergic modulation, neurotransmitter signalling) overlap with the targets of several psychotropic medications. The drug-interaction literature is small but the conservative position is to disclose any supplement to the prescriber managing your mental-health medication.
Does Bacopa cause nausea?
GI complaints — nausea, cramping, soft stools — are the most commonly reported side effect, particularly when Bacopa is taken on an empty stomach. Taking it with food substantially reduces this. If GI symptoms persist, lower the dose or consider a different ingredient.
🔬 Camden’s evidence review
The research Camden reviewed, graded on its strength. This is our own appraisal — it sits beneath the official guidance above, never above it.
Cognitive function in healthy adults — chronic use
LimitedEvidencelimitedSmall RCTs of standardised Bacopa extract (BacoMind® 320 mg/day or Bacopa CDRI 08 300 mg/day) for 8–12 weeks have reported modest improvements in delayed verbal recall and information processing speed. Trial sizes are small, durations short, and independent large-scale replication is limited. The most commonly cited meta-analysis (Kongkeaw 2014) pooled 9 trials with consistent direction of effect on delayed recall. EFSA cognitive-function claims for Bacopa are on hold.
Cognitive function in older adults with subjective complaints
LimitedEvidencelimitedSome trials have specifically explored Bacopa in older adults with subjective cognitive complaints. Effect sizes broadly match the healthy-adult literature. UK NICE pathways for cognitive concerns do not list Bacopa. [2]
ADHD / paediatric attention
InsufficientEvidenceinsufficientA small number of trials in children with ADHD have reported attention-score changes with Bacopa. UK NICE pathways for ADHD apply (NG87). Self-supplementation in children with ADHD is not appropriate. [3]
Anxiety, depression, or other mood conditions
InsufficientEvidenceinsufficientSome trials have explored anxiety outcomes with Bacopa. Trial evidence is small and inconsistent. UK NHS pathways for anxiety and mood conditions apply. [7]
Safety
Bacopa is generally well-tolerated when taken with food. GI complaints are common on an empty stomach. There are no major safety signals at standard supplement doses for healthy adults; pregnancy data is limited.
Talk to your pharmacist or GP first if you:
- You take prescribed antidepressants, anti-anxiety, or attention medications — disclose use; possible additive neurotransmitter effects.
- You take prescribed medications metabolised by CYP enzymes — Bacopa has theoretical effects on hepatic metabolism.
- You take thyroid medication (levothyroxine) — Bacopa has been associated with thyroid hormone fluctuations in animal studies.
- You have asthma, COPD, or peptic ulcer disease — traditional cautions in Ayurvedic literature; mechanism uncertain.
- You are pregnant, breastfeeding, or trying to conceive — limited safety data.
- You are giving any supplement to a child for ADHD — talk to the GP managing them.
Common side effects: GI complaints (nausea, cramping, soft stools, bloating) — particularly on an empty stomach. Mild fatigue or dry mouth less commonly reported.
Pregnancy and breastfeeding
Limited safety data in pregnancy; standard Ayurvedic and modern advice is to avoid Bacopa supplementation in pregnancy.
Limited safety data; avoid.
Talk to your GP, midwife, or pharmacist before starting any supplement during pregnancy or breastfeeding.
More clinical detail (for clinicians and informed readers)
Contraindications
- Known hypersensitivity to Bacopa or supplement constituents.
Drug interactions
- Antidepressants (SSRIs, SNRIs, tricyclics) — possible additive neurotransmitter effects; disclose use.
- Cholinergic / anticholinergic medications — possible additive or opposing effects.
- Thyroid medication (levothyroxine) — possible interaction; disclose use.
- CYP-metabolised medications — possible hepatic-metabolism effects.
This is not an exhaustive list. Always tell your prescriber and pharmacist about every supplement you take.
Common side effects
- GI complaints — nausea, abdominal cramping, soft stools, bloating; substantially reduced by taking with food.
Rare side effects
- Mild fatigue, dry mouth.
- Allergic reactions — uncommon.
How to take it
- Typical supplemental range
- Trials of standardised Bacopa extract have most commonly used 300–450 mg/day of extract standardised to ≥20% bacosides (e.g. Bacopa CDRI 08 300 mg/day; BacoMind® 320 mg/day). Whole-herb powder at the same milligram delivers a lower bacoside dose and is not directly comparable.
- Timing
- Daily — take with food to reduce GI complaints. Effects emerge over 8–12 weeks; acute / single-dose effects are not reliable.
How to spot quality
Look for
- Standardisation declared: bacoside A content (typically 20–55%) — the relevant quality marker.
- Branded research-grade preparation (Bacopa CDRI 08 or BacoMind®) for trial-matched material.
- mg of extract per serving stated; bacoside A mg per serving calculable.
- GMP-certified manufacture; ideally heavy-metal screen (Ayurvedic herbal preparations have historically had heavy-metal contamination concerns).
- Country of cultivation declared (predominantly India).
Red flags
- Generic "Bacopa monnieri powder" or "Brahmi powder" at the same milligram as standardised extract — unstandardised material.
- No bacoside A percentage declared.
- Marketing as "natural Adderall" / "smart drug" / nootropic acute effect.
- Same-day cognitive boost claims.
- "10:1" / "20:1" extract ratios marketed as potency without bacoside standardisation.
- No heavy-metal testing disclosure for Ayurvedic-sourced material.
Commonly combined with
Other ingredients that share a biological pathway, cofactor relationship, or evidence-backed protocol with this one. Mechanisms below cite primary physiology — not folk pairing. Doses are literature ranges, not recommendations. Talk to your pharmacist or GP before changing your stack, especially if you take prescription medication.
Lion's Mane
Limited evidenceTwo cognitive nootropics with different mechanisms — frequently combined in cognitive stacks for complementary action.
Bacopa monnieri bacosides modulate brain-derived neurotrophic factor (BDNF), antioxidant defences (superoxide dismutase, catalase), and cholinergic neurotransmission via acetylcholinesterase inhibition. Lion's Mane (Hericium erinaceus) acts on a different axis — hericenones and erinacines have cell-culture evidence for stimulating nerve growth factor (NGF) synthesis. The two are commonly stacked in nootropic formulations because their mechanisms are complementary, not overlapping. Most published trials test each compound alone; direct combination RCTs are rare. Bacopa requires sustained 8–12 week dosing for measurable cognitive endpoints (Stough 2008); Lion's Mane evidence is largely mechanistic with one well-cited Japanese MCI trial (Mori 2009).
Evidence: Stough 2008 (Phytother Res) on Bacopa cognitive function in healthy adults. Mori 2009 (Phytother Res) RCT on Lion's Mane in mild cognitive impairment. Combination evidence is mostly anecdotal and from commercial nootropic stacks. [8,9]
Doses studied: 300–450 mg Bacopa (50–55% bacoside extract) with 500–1000 mg Lion's Mane (8:1 hot-water extract) daily; minimum 8-week trial period for cognitive endpoints